Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

August Campaign Highlights Total Wellness for Over 8 Million in the U.S. with Psoriasis ALEXANDRIA, VA, UNITED STATES, August 1, 2025 /EINPres ...

Mentoring those newly diagnosed with psoriasis reminds a self-described old-timer of the value of lifestyle, community, and testing one’s limits.

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...